Anti-Golimumab ELISA Assay Kit

$1,250.00

The Anti-Golimumab ELISA Assay Kit is used as an analytical tool for quantitative determination of Anti-Golimumab in serum, plasma and cell culture supernatant.

Anti-Golimumab ELISA Assay Kit

The Anti-Golimumab ELISA Assay Kit is For Research Use Only

Size: 12×8 wells
Sensitivity: <10 ng/mL
Standard Range: 10-640 ng/ml
Incubation Time: 2.25 hours
Sample Type: Serum, Plasma, Cell Culture Supernatants
Sample Size: 100 µL
Alternative Name: Simponi


Assay Background

Golimumab (CNTO 148) is a human monoclonal antibody which is used as an immunosuppressive drug and marketed under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a proinflammatory molecule and hence is a TNF inhibitor. Profound reduction in C-reactive protein (CRP) levels, interleukin (IL)-6, intercellaular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism. Anti-Drug Antibodies (ADA) may induce unwanted side effects in biopharmaceuticals. Hence, ADA has been subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies. ADA has been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology, pharmacokinetics and efficacy. These effects result from the generation of drug-induced (neutralizing) autoantibodies against Golimumab and can be responsible for allergic reaction, or even anaphylactic shock. This ELISA kit detects antibodies for Anti-Golimumab and may be used for monitoring immunogenicity.


Related Products

Golimumab ELISA Assay Kit
Golimumab mAb-based ELISA Assay
Anti-Natalizumab (Tysabri) ELISA Assay Kit

Additional Information

Assay Principle


The method employs the quantitative sandwich enzyme immunoassay technique. Golimumab is pre-coated onto microwells. Samples and standards are pipetted into microwells and antibodies to Golimumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Golimumab is pipetted and incubated. After washing microwells in order to remove any nonspecific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anti-Golimumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Assay Procedure


It is strongly recommended that all Controls and Samples be run in duplicates or triplicates. A standard curve is required for each assay. All steps must be performed at 37°C.

  1. Pipette out 50 μl of Assay Diluent in each well.
  2. Add 100 μl of Standards or Samples into the respective wells.
  3. Cover the plate and incubate for 60 minutes at 37°C.
  4. Aspirate and wash plate 4 times with Wash Buffer (1X) and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe off any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step.
  5. Pipette without delay in the same order 100 μl of Golimumab: HRP Conjugate into each well.
  6. Cover the plate and incubate for 60 minutes at 37°C.
  7.  Aspirate and wash plate 4 times with Wash Buffer (1X) and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe off any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step.
  8. Add 100 μl of TMB Substrate in each well.
  9. Incubate the plate at 37°C for 15 minutes in dark. DO NOT SHAKE or else it may result in higher backgrounds and worse precision. Positive wells should turn bluish in color.
  10. Pipette out 100 μl of Stop Solution. Wells should turn from blue to yellow in color.
  11. Read the absorbance at 450 nm with a microplate reader.

Documents

Product Documents